Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.

BloodOct 1, 2026
Clinical ResearchOncology (Medical)

Sairah Ahmed, Alejandro Martín García-Sancho, Juan Luis Reguera Ortega et al.

✦ AI-curated · Sources linked

In 30 seconds

The TRANSCEND FL study evaluated the long-term efficacy and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory follicular lymphoma (FL) after at least two prior therapies. In a Phase III multicenter trial with 107 patients, the overall response rate was 97% and the complete response rate was 94%. After three years, the estimated overall survival rate was 86%.

Key findings

  • Overall response rate was 97% (95% CI, 92-99) and complete response rate was 94% (95% CI, 88-98).
  • 36-month overall survival rate was 86% (95% CI, 78-92).
  • Durations of response and progression-free survival were estimated at 70% and 68%, respectively.
  • Grade ≥3 cytopenias and infections decreased over time with supportive care.

Why it matters

This study highlights the durable efficacy and manageable safety profile of liso-cel in a challenging patient population, providing valuable insights for treatment options in relapsed/refractory follicular lymphoma.

Source

PubMed · PMID 42462111

Published in Blood. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.